BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BioXcel Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$44.93M. For fiscal 2025 it was -$50.46M. The highest annual figure on record is -$4.54M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.46M | – |
| FY2024 | Dec 31, 2024 | -$67.25M | – |
| FY2023 | Dec 31, 2023 | -$171.78M | – |
| FY2022 | Dec 31, 2022 | -$159.65M | – |
| FY2021 | Dec 31, 2021 | -$106.94M | – |
| FY2020 | Dec 31, 2020 | -$82.30M | – |
| FY2019 | Dec 31, 2019 | -$33.60M | – |
| FY2018 | Dec 31, 2018 | -$19.96M | – |
| FY2017 | Dec 31, 2017 | -$4.54M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.19M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.23M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$48.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$52.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$52.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$38.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$36.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.13M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.81M | – |
| Q2 FY2021 | Jun 30, 2021 | -$27.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$26.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.77M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.44M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.41M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.13M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.31M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.12M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.29M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.53M | – |
| Q3 FY2017 | Sep 30, 2017 | -$917.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$565.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$529.00K | – |
See a number that looks wrong?